Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 10;11(6):951. doi: 10.3390/cells11060951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Quantification of graft size in animals receiving CCND2 overexpressing hiPSC-CMs. Immediately after surgically induced myocardial infarction, the mice received intramyocardial injection of 1 million hiPSC-CCND2^OE/Luci^OECMs. Control mice received intramyocardial injection of PBS after myocardial infarction induction. The transplanted cells carried a luciferase reporter plasmid and were of human origin; thus, engraftment was evaluated via bioluminescence imaging at 6 months after cell transplantation. (A) A standard curve was generated from bioluminescence measurements of known quantities of hiPSC-CMs. (B) Six months after myocardial infarction induction and treatment with intramyocardial injections of PBS (n = 6 animals) or hiPSC-CCND2^OE/Luci^OECMs (n = 10 animals), the mice were injected with luciferin, and bioluminescence images were collected 10 min later. Bioluminescence signal intensity was compared to the standard curve to determine the number of engrafted cells; then, the engraftment rate was calculated by dividing the number of engrafted cells by the total number of cells administered and expressed as a percentage. *—p < 0.05 versus PBS-receiving group by Student’s t-test.